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To the Editor,
We read the Letter to the Editor by Wang and Xing, 2019, 
entitled “AcroVoice: the controversial values in reflecting 
acromegaly disease activity” with some concern [1]. The 
authors misinterpreted the ACRODAT® study, and there 
is a need to correct this. Wang and Xing, 2019 presented a 
critique of the ACRODAT® study, not AcroVoice, and did 
not even reference the ACRODAT® paper [2] in their Let-
ter to the Editor [1]. Moreover, Wang and Xing expressed 
concerns regarding the “rationality of the five parameters of 
ACRODAT®” [1].
As has been published, ACRODAT® was developed with 
expert opinion and validated in a rigorous study [2]. The 
resulting five dimensions (tumor status, insulin-like growth 
factor I [IGF-I] levels, comorbid conditions [diabetes, sleep 
apnea, and cardiac disease], symptoms, and quality of life 
[QoL]) offer a fast, simple tool to obtain an overview of 
patients’ disease and, when needed, help make informed 
treatment decisions [2]. The dimensions of ACRODAT® 
were carefully chosen to produce a balance between being 
practical to use and inclusive with respect to its power to 
reflect all of the important information on disease activity in 
acromegaly. Moreover, the dimensions of ACRODAT® are 
used by patients to gauge the severity of their disease, high-
lighting the importance of all components of acromegaly in 
the assessment of their condition. The inclusion of additional 
data or dimensions was evaluated by the expert panel; it was 
believed this did not add to the tool, and additionally, may 
confound potential issues in disease management.
With regard to the AcroVoice study, Wang and Xing 
raised concerns about the variability in patients’ responses 
to the discrete choice experiment (DCE) questions [1]. How-
ever, AcroVoice also employed a rigorous study design and 
the responses from the sample size of 100 patients exhibited 
a normal distribution, as would be expected from a large 
cohort, for which a pre-determined statistical analysis was 
employed to ascertain the robustness of the responses [3]. 
Moreover, Wang and Xing raised concerns that the patients’ 
responses or selections were too subjective since no specific 
values were used to define “slight” or “significant” abnor-
malities [1]. Again, the assumption is not accurate, and in 
fact, specific values were ascribed to slight or significant 
abnormalities for each parameter.
ACRODAT® and AcroVoice offer insights into a holistic 
approach to the management of acromegaly [2, 3]. Impor-
tantly, the AcroVoice study considered the patients’ perspec-
tives surrounding their care and highlighted the strong desire 
of patients to have an active role in their disease manage-
ment [3]. The AcroVoice study showed that patients with 
acromegaly valued both clinical factors and patient-centered 
factors. The study emphasized the importance of personal-
ized care [3]. The AcroVoice study also showed that shared 
decision-making between patients and their doctors is 
important in making treatment decisions [3]. To support this 
conversation between patients and their healthcare providers, 
a Plain Language Summary (https ://www.acrom egaly west.
com/blog) was developed.
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